12:00 AM
Aug 02, 2010
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Viramune XR nevirapine: Phase III data

In the double-blind, double-dummy, active-controlled Phase III VERxVE trial in 1,011 treatment-naïve HIV patients, once-daily 400 mg Viramune XR was non-inferior to twice-daily immediate-release 200 mg Viramune IR on the primary endpoint of proportion of patients achieving a confirmed virologic response through week 48 (81% vs. 75.9%). Furthermore, response rates in patients...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >